Microbiota transplant to cancer patients who have failed immunotherapy using feces from clinical responders | NCT05286294 | Melanoma; head and neck squamous cell carcinoma; cutaneous squamous cell carcinoma; clear cell renal cell carcinoma; non-small cell lung cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 20 | RECRUITING |
Washed microbiota transplantation for the treatment of oncotherapy-related intestinal complications | NCT04721041 | Cancer | INTERVENTIONAL | SINGLE_GROUP | / | 40 | RECRUITING |
Utilization of microbiome as biomarkers and therapeutics in immuno-oncology | NCT04264975 | Solid carcinoma | INTERVENTIONAL | SINGLE_GROUP | / | 60 | UNKNOWN |
FMT in treating immune-checkpoint inhibitor induced-diarrhea or colitis in genitourinary cancer patients | NCT04038619 | Malignant genitourinary system neoplasm; melanoma; lung cancer; ovarian cancer; uterine cancer; breast cancer; cervical cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 40 | RECRUITING |
FMT in checkpoint inhibitor-mediated diarrhea and colitis | NCT06206707 | Malignant melanoma; kidney cancer | INTERVENTIONAL | PARALLEL; Masking: DOUBLE (PARTICIPANT, INVESTIGATOR) | / | 20 | RECRUITING |
FMT in patients with malignancies not responding to cancer immunotherapy | NCT05273255 | Cancer | INTERVENTIONAL | SINGLE_GROUP | / | 30 | RECRUITING |
Efficacy and safety of FMT in reducing recurrence of colorectal adenoma | NCT06205862 | Colorectal adenoma | INTERVENTIONAL | PARALLEL; Masking: DOUBLE (PARTICIPANT, INVESTIGATOR) | PHASE2 | 466 | RECRUITING |
FMT in metastatic melanoma patients who failed immunotherapy | NCT03353402 | Melanoma | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 40 | UNKNOWN |
Preventing toxicity in renal cancer patients treated with immunotherapy using FMT | NCT04163289 | Renal cell carcinoma | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 20 | ACTIVE_NOT_RECRUITING |
FMT with immune checkpoint inhibitors in lung cancer | NCT05502913 | Metastatic lung cancer | INTERVENTIONAL | PARALLEL; Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR) | PHASE2 | 80 | RECRUITING |
FMT in melanoma patients | NCT03341143 | Melanoma | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 18 | ACTIVE_NOT_RECRUITING |
Inducing remission in melanoma patients with Checkpoint Inhibitor therapy using FMT. | NCT04577729 | Malignant melanoma | INTERVENTIONAL | PARALLEL; Masking: DOUBLE (PARTICIPANT, INVESTIGATOR) | / | 5 | TERMINATED |
FMT to convert the response to immunotherapy | NCT05251389 | Melanoma | INTERVENTIONAL | PARALLEL; Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR) | PHASE2 | 24 | RECRUITING |
FMT and pembrolizumab for men with metastatic castration-resistant prostate cancer. | NCT04116775 | Prostate cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 32 | UNKNOWN |
Chemotherapy and stool transplant in pancreatic ductal adenocarcinoma (PDAC) | NCT06393400 | Unresectable or metastatic advanced pancreatic ductal adenocarcinoma | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 20 | NOT_YET_RECRUITING |
FMT in patients with advanced gastric cancer | NCT06346093 | Advanced gastric cancer | INTERVENTIONAL | PARALLEL; Masking: DOUBLE (PARTICIPANT, INVESTIGATOR) | / | 66 | RECRUITING |
A single dose FMT infusion as an adjunct to Keytruda for metastatic mesothelioma | NCT04056026 | Mesothelioma | INTERVENTIONAL | SINGLE_GROUP | EARLY_PHASE1 | 1 | COMPLETED |
FMT in diarrhea induced by tyrosine-kinase inhibitors | NCT04040712 | Renal cell cancer | INTERVENTIONAL | PARALLEL; Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR) | / | 20 | COMPLETED |
FMT for the treatment of pancreatic cancer | NCT04975217 | Pancreatic ductal adenocarcinoma | INTERVENTIONAL | SINGLE_GROUP | EARLY_PHASE1 | 10 | RECRUITING |
Microbiota transplant in advanced lung cancer treated with immunotherapy | NCT04924374 | Lung cancer | INTERVENTIONAL | PARALLEL; Masking: NONET | / | 20 | RECRUITING |
Prevention of dysbiosis complications with autologous FMT in AML patients | NCT02928523 | Leukemia, myeloid, acute | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 20 | COMPLETED |
Fecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab | NCT05690048 | Immunotherapy | INTERVENTIONAL | PARALLEL; Masking: SINGLE (PARTICIPANT) | PHASE2 | 48 | NOT_YET_RECRUITING |
FMT and re-introduction of anti-programmed death 1 (anti-PD-1) therapy (Pembrolizumab or Nivolumab) for the treatment of metastatic colorectal cancer in anti-PD-1 non-responders | NCT04729322 | Metastatic colorectal adenocarcinoma | INTERVENTIONAL | PARALLEL; Masking: NONE | PHASE2 | 15 | ACTIVE_NOT_RECRUITING |
FMT capsule for improving the efficacy of anti-PD-1 | NCT04130763 | Gastrointestinal system cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 10 | ACTIVE_NOT_RECRUITING |
FMT+chemotherapy+Sintilimab as first-line treatment for advanced gastric cancer | NCT06405113 | Gastric cancer | INTERVENTIONAL | PARALLEL; Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR) | PHASE2 | 198 | NOT_YET_RECRUITING |
FMT with nivolumab in patients with advanced solid cancers who have progressed during anti-PD-1 therapy | NCT05533983 | Solid carcinoma | INTERVENTIONAL | SINGLE_GROUP | / | 50 | NOT_YET_RECRUITING |
Responder-derived FMT (R-FMT) and pembrolizumab in relapsed/refractory programmed death ligand 1 (PD-L1) positive non-small cell lung cancer | NCT05669846 | Non-small cell lung cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 26 | NOT_YET_RECRUITING |
A study of FMT in patients with acute myeloid leukemia allogeneic hematopoietic cell transplantation in recipients | NCT03678493 | Acute myeloid leukemia | INTERVENTIONAL | PARALLEL; Masking: NONE | PHASE2 | 100 | COMPLETED |
FMT combined with immune checkpoint inhibitor and tyrosine kinase inhibitors in the treatment of colorectal cancer patients with advanced stage | NCT05279677 | Colorectal neoplasms malignant | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 30 | UNKNOWN |
Intestinal microbiota transplant prior to allogeneic stem cell transplant trial | NCT06355583 | Acute lymphoblastic leukemia | INTERVENTIONAL | PARALLEL; Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR) | PHASE2 | 50 | NOT_YET_RECRUITING |
Pilot trial of FMT for lymphoma patients receiving axicabtagene ciloleucel therapy. | NCT06218602 | Lymphoma | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 40 | RECRUITING |
FMT+immunotherapy+chemotherapy as first-line treatment for driver-gene negative advanced non-small cell lung cancer | NCT06403111 | Non-small cell lung cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 62 | NOT_YET_RECRUITING |
Role of the gut microbiome and fecal transplant on medication-induced gastrointestinal complications in patients with cancer | NCT03819296 | Melanoma | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 800 | RECRUITING |
Assessing the tolerance and clinical benefit of fecal transplantation in patients with melanoma | NCT04988841 | Melanoma | INTERVENTIONAL | PARALLEL; Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR) | PHASE2 | 60 | RECRUITING |
FMT to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma | NCT04758507 | Renal cell carcinoma | INTERVENTIONAL | PARALLEL; Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR) | PHASE2 | 50 | ACTIVE_NOT_RECRUITING |
Gut microbiota reconstruction for immunotherapy | NCT05008861 | Non-small cell lung cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 20 | UNKNOWN |
Impact of oral nutritional supplements on patients undergoing hematopoietic stem cell transplantation | NCT05460013 | Hematological malignancy | INTERVENTIONAL | PARALLEL; Masking: SINGLE (PARTICIPANT) | NA | 100 | RECRUITING |
RBX7455 before surgery for the treatment of operable breast cancer | NCT04139993 | Breast cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE1 | 3 | TERMINATED |
FMT combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who failed to respond to prior immunotherapy | NCT05750030 | Hepatocellular carcinoma | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 12 | RECRUITING |
Pembrolizumab/Lenvatinib with and without responder-derived FMT in relapsed/refractory melanoma | NCT06030037 | PD-1 refractory advanced melanoma | INTERVENTIONAL | PARALLEL; Masking: NONE | PHASE2 | 56 | NOT_YET_RECRUITING |
Oral immunonutrition with synbiotics, Omega 3, and vitamin D in patients undergoing duodenopancreatectomy for tumoral lesion. | NCT05271344 | Pancreatic cancer | INTERVENTIONAL | PARALLEL; Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR) | / | 74 | RECRUITING |
Feasibility study of microbial ecosystem therapeutics to evaluate effects of fecal microbiome in patients on immunotherapy | NCT03686202 | All solid tumors | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 65 | ACTIVE_NOT_RECRUITING |
Role of microbiome as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma 2 | NCT03838601 | Head and neck squamous cell carcinoma | INTERVENTIONAL | SINGLE_GROUP | / | 30 | ACTIVE_NOT_RECRUITING |
Microbiota and pancreatic cancer cachexia | NCT05606523 | Pancreatic cancer | OBSERVATIONAL | Observational Model | / | 24 | RECRUITING |
Role of gut microbiome in cancer therapy | NCT05112614 | Hematopoietic and lymphoid cell neoplasm; malignant solid neoplasm | OBSERVATIONAL | Observational Model | / | 5,000 | RECRUITING |
The effect of gut microbiota on postoperative liver function recovery in patients with hepatocellular carcinoma | NCT04303286 | Hepatocellular carcinoma | OBSERVATIONAL | Observational Model | / | 200 | COMPLETED |
The gut microbiome in acute myeloid leukemia with FLT3 mutation undergoing allogeneic hematopoietic stem cell transplantation with or without sorafenib maintenance | NCT05601895 | Acute leukemia | OBSERVATIONAL | Observational Model | / | 60 | RECRUITING |
The mechanism of enhancing the anti-tumor effects of chimeric antigen receptor T-cell immunotherapy on pancreatic cancer by gut microbiota regulation | NCT04203459 | Pancreatic cancer | OBSERVATIONAL | Observational Model | / | 80 | UNKNOWN |
The gut microbiome in acute myeloid leukemia with FMS-like tyrosine kinase-3/internal tandem duplication (FLT3/ITD) mutation undergoing allogeneic hematopoietic stem cell transplantation with or without sorafenib maintenance after allogeneic hematopoietic stem cell transplantation | NCT05596981 | Acute myeloid leukemia with FLT3/ITD mutation | OBSERVATIONAL | Observational Model | / | 60 | RECRUITING |
The gut microbiome and sorafenib maintenance therapy in FLT3/ITD positive cute myeloid leukemia after allogeneic hematopoietic stem cell transplantation | NCT05596968 | Acute myeloid leukemia with FLT3/ITD mutation | OBSERVATIONAL | Observational Model | / | 37 | RECRUITING |
Multiple myeloma outcomes based on maintenance therapy post autologous stem cell transplant | NCT05271630 | Multiple myeloma | OBSERVATIONAL | Observational Model | / | 69 | RECRUITING |
Fecal bacteria transplantation in the treatment of patients with advanced cancer | ChiCTR2100049431 | Liver, colon, gastric, pancreatic, and lung cancer | INTERVENTIONAL | SINGLE_GROUP | PHASE2 | 50 | UNKNOWN |